诺和锐特充治疗妊娠期糖尿病的临床疗效

Analysis on the clinical effect of insulin aspart injection in treatment of gestational diabetes mellitus

目的研究应用诺和锐特充治疗妊娠期糖尿病患者的临床疗效及安全性,为改善妊娠结局,降低妊娠并发症提供理论依据。方法抽取2015年1月-2016年12月在该院接受治疗的妊娠期糖尿病患者60例进行研究,随机分为观察组和对照组,每组各30例。对照组给予诺和灵R进行治疗,用药4周;观察组给予诺和锐特充治疗,用药4周。比较两组患者的血糖、胰岛素抵抗指数变化情况,分析母婴结局与新生儿低血糖发生率。结果治疗后,观察组患者的空腹血糖与餐后2 h血糖均较治疗前明显下降,且降幅较对照组明显(P<0.05);HOMA-IR明显低于治疗前与对照组治疗后(P<0.05);观察组中新生儿低血糖比例、妊娠期高血压疾病比例、羊水过多以及新生儿呼吸窘迫综合征比例均明显低于对照组(P<0.05);两组患者低血糖发生率比较差异无统计学意义(P<0.05)。结论应用诺和锐特充治疗妊娠期糖尿病可对患者的血糖水平进行有效控制,改善母婴结局,用药安全。

Objective To research the clinical effect and safety of insulin aspart injection in treatment of gestational diabetes mellitus（GDM）,provide a theoretical basis for improving pregnancy outcomes and reducing pregnancy complications.Methods Sixty GDM patients treated in the Second Hospital of Yulin from Janaury 2015 to December 2016 were selected and randomly divided into observation group and control group,30 patients in each group.The patients in control group were treated by Novolin R for 4 weeks,and the patients in observation group were treated by insulin aspart injection for 4 weeks.The changes of blood glucose and insulin resistance index in the two groups were compared.The outcomes of mothers and infants and the incidence rate of neonatal hypoglycemia were analyzed.Results After treatment,fasting glucose and postprandial 2-hour blood glucose in observation group were statistically significantly lower than those before treatment,and the decreasing amplitude was statistically significantly larger than that in control group（P0.05）.HOMA-IR after treatment in observation group was statistically significantly lower than those before treatment and after treatment in control group（P0.05）.The incidence rates of neonatal hypoglycemia,hypertensive disorder complicating pregnancy,polyhydramnios,and neonatal respiratory distress syndrome in observation group were statistically significantly lower than those in control group（P0.05）.Conclusion Insulin aspart injection can effectively control blood glucose levels of GDM patients and improve outcomes of mothers and infants,and the therapy is safe.